Literature DB >> 18820568

Universal influenza vaccination and live attenuated influenza vaccination of children.

W Paul Glezen1.   

Abstract

Influenza is an uncontrolled epidemic disease that is vaccine preventable. Each winter the peak of medically attended acute respiratory illness coincides with the peak of influenza virus activity. The anatomy of an urban influenza epidemic is presented highlighting the role of children in the spread of influenza. The efficacy and safety of the live attenuated influenza vaccine (LAIV) for children are documented and the indirect effectiveness (herd protection) of vaccinating schoolchildren is demonstrated. Children have the highest attack rates during influenza epidemics and the consequences of influenza virus infection can be severe regardless of the virus type--A(H1N1), A(H3N2), or B. Early in the epidemic, over one-half of the culture-positive illnesses will occur in school-aged children demonstrating their role in spreading the virus in the community. LAIV has been shown to be superior to inactivated vaccine for children and is safe even for children with mild intermittent asthma. One dose of LAIV is effective and gives almost immediate protection. LAIV administered by nasal spray is readily accepted by children. Several studies have demonstrated herd protection by immunizing schoolchildren. These studies have shown that immunizing schoolchildren is more efficient than vaccinating elderly and high-risk patients directly. Current recommendations for influenza vaccine give priority to more than 200 million persons in the United States, but vaccine coverage has not improved since 1997. Systematic delivery of influenza vaccine in school-based and workplace-based clinics would greatly enhance the control of epidemic influenza and help prepare for the next pandemic.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18820568     DOI: 10.1097/INF.0b013e318168b729

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  7 in total

1.  Timeliness of pediatric influenza vaccination compared with seasonal influenza activity in an urban community, 2004-2008.

Authors:  Annika M Hofstetter; Karthik Natarajan; Daniel Rabinowitz; Raquel Andres Martinez; David Vawdrey; Stephen Arpadi; Melissa S Stockwell
Journal:  Am J Public Health       Date:  2013-05-16       Impact factor: 9.308

2.  In reply.

Authors:  Peter Wutzler
Journal:  Dtsch Arztebl Int       Date:  2014-02-28       Impact factor: 5.594

3.  Differential localization and function of antibody-forming cells responsive to inactivated or live-attenuated influenza virus vaccines.

Authors:  Robert Sealy; Richard J Webby; Jeri C Crumpton; Julia L Hurwitz
Journal:  Int Immunol       Date:  2012-11-08       Impact factor: 4.823

4.  Influenza-related mortality trends in Japanese and American seniors: evidence for the indirect mortality benefits of vaccinating schoolchildren.

Authors:  Vivek Charu; Cécile Viboud; Lone Simonsen; Katharine Sturm-Ramirez; Masayoshi Shinjoh; Gerardo Chowell; Mark Miller; Norio Sugaya
Journal:  PLoS One       Date:  2011-11-07       Impact factor: 3.240

5.  Molecular characterization of influenza viruses collected from young children in Uberlandia, Brazil - from 2001 to 2010.

Authors:  Thelma Fátima de Mattos Silva Oliveira; Jonny Yokosawa; Fernando Couto Motta; Marilda Mendonça Siqueira; Hélio Lopes da Silveira; Divina Aparecida Oliveira Queiróz
Journal:  BMC Infect Dis       Date:  2015-02-18       Impact factor: 3.090

6.  Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States.

Authors:  Nicole E Basta; Dennis L Chao; M Elizabeth Halloran; Laura Matrajt; Ira M Longini
Journal:  Am J Epidemiol       Date:  2009-08-13       Impact factor: 4.897

Review 7.  Clinical Expectations for Better Influenza Virus Vaccines-Perspectives from the Young Investigators' Point of View.

Authors:  Kristin G-I Mohn; Fan Zhou
Journal:  Vaccines (Basel)       Date:  2018-05-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.